Table 3.

Anti-trichomonal activities of subfractions E_1–13.

Subfractions/Drug	24 hrs		48 hrs
	LC50 (µg/ml)	LC90 (µg/ml)	LC50 (µg/ml)	LC90 (µg/ml)
C2	36.43± 2.73*,†	265.34± 9.43†	18.05± 5.09	156.95± 5.68†
E1	131.71 ± 1.38*,†	2363.73 ± 9.33*,†	133.37 ±2.04*,†	2124.73 ±12.72*,†
E2	4.95 ± 0.78*,†	20.93 ± 1.92*	3.61 ± 2.54*,†	18.69 ± 2.96*,†
E3	5.61± 1.30*,†	20.72 ± 3.29*	3.24 ± 0.63*,†	16.28 ± 2.03*,†
E4	4.77 ± 0.83*,†	18.49 ± 2.94*	4.53 ± 1.23*,†	18.38 ± 3.70*,†
E5	7.28 ± 0.87*,†	25.00 ± 2.95*	4.95 ± 0.81*,†	19.07 ± 2.20*,†
E6	40.28 ± 0.85†	168.04 ± 8.27*,†	22.53 ± 1.38†	157.95 ± 6.31†
E7	32.78 ± 1.28†	182.67 ± 4.63*,†	33.38 ± 0.85*,†	207.89 ± 7.64†
E8	84.27 ± 0.75*,†	935.05 ± 11.11*,†	58.11± 0.99*,†	565.03 ± 9.30*,†
E9	61.55 ± 0.93*,†	828.32 ± 4.06*,†	63.40 ± 0.66*,†	551.64 ± 7.22*,†
E10	60.73 ± 0.79*,†	694.85 ± 5.53*,†	58.87 ± 1.45*,†	390.53 ± 8.14*,†
E11	69.15 ± 0.09*,†	725.31 ± 9.33*,†	78.63 ± 0.64*,†	639.83 ± 3.57*,†
E12	69.28 ± 1.22*,†	507.34 ± 3.27*,†	89.16 ± 0.44*,†	680.21 ± 6.99*,†
E13	70.46 ± 0.37*,†	735.55 ± 9.27*,†	124.46 ± 0.87*,†	959.10 ± 6.63*,†
Metronidazole	13.67 ± 0.03*	42.86 ± 0.87*	14.04 ± 1.95	61.37 ± 8.69*

E_1–13: VLC subfractions of an active VLC fraction C₂. N = 9; p < 0.05; *: LC₅₀ and LC₉₀ vs C₂; ^†: LC₅₀ and LC₉₀ vs metronidazole. LC₅₀ and LC₉₀: Values ± SEM.